{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:06:31Z","timestamp":1792670791390,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current study describes a scalable, porous large-format engineered cardiac tissue (LF-ECT) composed of human induced pluripotent stem cells (hiPSCs) derived multiple lineage cardiac cells with varied 3D geometries and cell densities developed towards the goal of scale-up for large animal pre-clinical studies. We explored multiple 15\u2009\u00d7\u200915\u2009mm ECT geometries using molds with rectangular internal staggered posts (mesh, ME), without posts (plain sheet, PS), or long parallel posts (multiple linear bundles, ML) and a gel matrix containing hiPSC-derived cardiomyocytes, endothelial, and vascular mural cells matured <jats:italic>in vitro<\/jats:italic> for 14 days. ME-ECTs displayed the lowest dead cell ratio (p\u2009&lt;\u20090.001) and matured into 0.5\u2009mm diameter myofiber bundles with greater 3D cell alignment and higher active stress than PS-ECTs. Increased initial ECT cell number beyond 6\u2009M per construct resulted in reduced cell survival and lower active stress. The 6M-ME-ECTs implanted onto 1 week post-infarct immune tolerant rat hearts engrafted, displayed evidence for host vascular coupling, and recovered myocardial structure and function with reduced scar area. We generated a larger (30\u2009\u00d7\u200930\u2009mm) ME-ECT to confirm scalability. Thus, large-format ECTs generated from hiPSC-derived cardiac cells may be feasible for large animal preclinical cardiac regeneration paradigms.<\/jats:p>","DOI":"10.1038\/srep45641","type":"journal-article","created":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T10:22:44Z","timestamp":1491214964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Impact of Cell Composition and Geometry on Human Induced Pluripotent Stem Cells-Derived Engineered Cardiac Tissue"],"prefix":"10.1038","volume":"7","author":[{"given":"Takeichiro","family":"Nakane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Masumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Tinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun K.","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley B.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,3]]},"reference":[{"key":"BFsrep45641_CR1","doi-asserted-by":"crossref","unstructured":"Mozaffarian, D. et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation, doi: 10.1161\/CIR.0000000000000350 (2015).","DOI":"10.1161\/CIR.0000000000000350"},{"key":"BFsrep45641_CR2","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(11)61590-0","volume":"378","author":"R Bolli","year":"2011","unstructured":"Bolli, R. et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378, 1847\u20131857 (2011).","journal-title":"Lancet"},{"key":"BFsrep45641_CR3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1161\/CIRCRESAHA.113.300219","volume":"113","author":"SK Sanganalmath","year":"2013","unstructured":"Sanganalmath, S. K. & Bolli, R. Cell therapy for heart failure: A comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ. Res. 113, 810\u2013834 (2013).","journal-title":"Circ. Res."},{"key":"BFsrep45641_CR4","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1038\/srep06716","volume":"4","author":"H Masumoto","year":"2014","unstructured":"Masumoto, H. et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Sci. Rep. 4, 6716 (2014).","journal-title":"Sci. Rep."},{"key":"BFsrep45641_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nature13233","volume":"510","author":"JJH Chong","year":"2014","unstructured":"Chong, J. J. H. et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273\u2013277 (2014).","journal-title":"Nature"},{"key":"BFsrep45641_CR6","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1161\/CIRCRESAHA.116.304386","volume":"116","author":"SA Fisher","year":"2015","unstructured":"Fisher, S. A., Doree, C., Mathur, A. & Martin-Rendon, E. Meta-Analysis of Cell Therapy Trials for Patients With Heart Failure. Circ. Res. 116, 1361\u20131377 (2015).","journal-title":"Circ. Res."},{"key":"BFsrep45641_CR7","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1093\/eurheartj\/ehv189","volume":"36","author":"P Menasch\u00e9","year":"2015","unstructured":"Menasch\u00e9, P. et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur. Heart J. 36, 2011\u20132017 (2015).","journal-title":"Eur. Heart J."},{"key":"BFsrep45641_CR8","doi-asserted-by":"publisher","first-page":"29933","DOI":"10.1038\/srep29933","volume":"6","author":"H Masumoto","year":"2016","unstructured":"Masumoto, H. et al. The myocardial regenerative potential of three-dimensional engineered cardiac tissues composed of multiple human iPS cell-derived cardiovascular cell lineages. Sci. Rep. 6, 29933 (2016).","journal-title":"Sci. Rep."},{"key":"BFsrep45641_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10741-016-9538-7","volume":"21","author":"J Mar\u00edn-Garc\u00eda","year":"2016","unstructured":"Mar\u00edn-Garc\u00eda, J. Cell death in the pathogenesis and progression of heart failure. Heart Fail. Rev. 21, 117\u2013121 (2016).","journal-title":"Heart Fail. Rev."},{"key":"BFsrep45641_CR10","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861\u201372 (2007).","journal-title":"Cell"},{"key":"BFsrep45641_CR11","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1016\/j.yexcr.2010.04.004","volume":"316","author":"JK Yamashita","year":"2010","unstructured":"Yamashita, J. K. ES and iPS cell research for cardiovascular regeneration. Exp. Cell Res. 316, 2555\u20132559 (2010).","journal-title":"Exp. Cell Res."},{"key":"BFsrep45641_CR12","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1161\/CIRCRESAHA.114.300556","volume":"114","author":"PA Lalit","year":"2014","unstructured":"Lalit, P. A., Hei, D. J., Raval, A. N. & Kamp, T. J. Induced Pluripotent Stem Cells for Post-Myocardial Infarction Repair: Remarkable Opportunities and Challenges. Circ. Res. 114, 1328\u20131345 (2014).","journal-title":"Circ. Res."},{"key":"BFsrep45641_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nm1394","volume":"12","author":"W-H Zimmermann","year":"2006","unstructured":"Zimmermann, W.-H. et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat. Med. 12, 452\u2013458 (2006).","journal-title":"Nat. Med."},{"key":"BFsrep45641_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1161\/CIRCRESAHA.110.237206","volume":"109","author":"NL Tulloch","year":"2011","unstructured":"Tulloch, N. L. et al. Growth of Engineered Human Myocardium With Mechanical Loading and Vascular Coculture. Circ. Res. 109, 47\u201359 (2011).","journal-title":"Circ. Res."},{"issue":"10","key":"BFsrep45641_CR15","doi-asserted-by":"publisher","first-page":"e26397","DOI":"10.1371\/journal.pone.0026397","volume":"6","author":"Sebastian Schaaf","year":"2011","unstructured":"Schaaf, S. et al. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One 6 (2011).","journal-title":"PLoS ONE"},{"key":"BFsrep45641_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCRESAHA.115.306985","volume":"117","author":"J Riegler","year":"2015","unstructured":"Riegler, J. et al. Human Engineered Heart Muscles Engraft and Survive Long Term in a Rodent Myocardial Infarction Model. Circ. Res. 117, 720\u2013730 (2015).","journal-title":"Circ. Res."},{"key":"BFsrep45641_CR17","doi-asserted-by":"publisher","first-page":"363ra148","DOI":"10.1126\/scitranslmed.aaf8781","volume":"8","author":"F Weinberger","year":"2016","unstructured":"Weinberger, F. et al. Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells. Sci. Transl. Med. 8, 363ra148\u2013363ra148 (2016).","journal-title":"Sci. Transl. Med."},{"key":"BFsrep45641_CR18","doi-asserted-by":"publisher","first-page":"H1829","DOI":"10.1152\/ajpheart.00205.2006","volume":"291","author":"K Tobita","year":"2006","unstructured":"Tobita, K. et al. Engineered early embryonic cardiac tissue retains proliferative and contractile properties of developing embryonic myocardium. Am. J. Physiol. Heart Circ. Physiol. 291, H1829\u201337 (2006).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFsrep45641_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/ten.tea.2010.0259","volume":"17","author":"KL Fujimoto","year":"2011","unstructured":"Fujimoto, K. L. et al. Engineered fetal cardiac graft preserves its cardiomyocyte proliferation within postinfarcted myocardium and sustains cardiac function. Tissue Eng. Part A 17, 585\u201396 (2011).","journal-title":"Tissue Eng. Part A"},{"key":"BFsrep45641_CR20","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/srep01316","volume":"3","author":"K Sakaguchi","year":"2013","unstructured":"Sakaguchi, K. et al. In vitro engineering of vascularized tissue surrogates. Sci. Rep. 3, 1316 (2013).","journal-title":"Sci. Rep."},{"key":"BFsrep45641_CR21","doi-asserted-by":"crossref","unstructured":"Sun, X., Altalhi, W. & Nunes, S. S. Vascularization strategies of engineered tissues and their application in cardiac regeneration. Adv. Drug Deliv. Rev., doi: 10.1016\/j.addr.2015.06.001 (2015).","DOI":"10.1016\/j.addr.2015.06.001"},{"key":"BFsrep45641_CR22","doi-asserted-by":"publisher","first-page":"16842","DOI":"10.1038\/srep16842","volume":"5","author":"T Matsuo","year":"2015","unstructured":"Matsuo, T. et al. Efficient long-term survival of cell grafts after myocardial infarction with thick viable cardiac tissue entirely from pluripotent stem cells. Sci. Rep. 5, 16842 (2015).","journal-title":"Sci. Rep."},{"key":"BFsrep45641_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13287-015-0237-4","volume":"6","author":"I Perea-Gil","year":"2015","unstructured":"Perea-Gil, I., Prat-Vidal, C. & Bayes-Genis, A. In vivo experience with natural scaffolds for myocardial infarction: the times they are a-changin\u2019. Stem Cell Res. Ther. 6, 248 (2015).","journal-title":"Stem Cell Res. Ther."},{"key":"BFsrep45641_CR24","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.biomaterials.2011.11.003","volume":"33","author":"R Gaetani","year":"2012","unstructured":"Gaetani, R. et al. Cardiac tissue engineering using tissue printing technology and human cardiac progenitor cells. Biomaterials 33, 1782\u20131790 (2012).","journal-title":"Biomaterials"},{"key":"BFsrep45641_CR25","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/nprot.2009.155","volume":"4","author":"W Bian","year":"2009","unstructured":"Bian, W., Liau, B., Badie, N. & Bursac, N. Mesoscopic hydrogel molding to control the 3D geometry of bioartificial muscle tissues. Nat. Protoc. 4, 1522\u201334 (2009).","journal-title":"Nat. Protoc."},{"key":"BFsrep45641_CR26","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1016\/j.biomaterials.2013.04.026","volume":"34","author":"D Zhang","year":"2013","unstructured":"Zhang, D. et al. Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials 34, 5813\u201320 (2013).","journal-title":"Biomaterials"},{"key":"BFsrep45641_CR27","doi-asserted-by":"publisher","first-page":"e65963","DOI":"10.1371\/journal.pone.0065963","volume":"8","author":"N Christoforou","year":"2013","unstructured":"Christoforou, N. et al. Induced pluripotent stem cell-derived cardiac progenitors differentiate to cardiomyocytes and form biosynthetic tissues. PLoS One 8, e65963 (2013).","journal-title":"PLoS One"},{"key":"BFsrep45641_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.stemcr.2016.04.011","volume":"7","author":"I Mannhardt","year":"2016","unstructured":"Mannhardt, I. et al. Human Engineered Heart Tissue: Analysis of Contractile Force. Stem Cell Reports 7, 29\u201342 (2016).","journal-title":"Stem Cell Reports"},{"key":"BFsrep45641_CR29","doi-asserted-by":"crossref","unstructured":"Me, C. Developmental Changes in Cardiomyocytes Differentiated from Human Embryonic Stem Cells: A Molecular and Electrophysiological Approach. 1136\u20131144, doi: 10.1634\/stemcells.2006-0466 (2007).","DOI":"10.1634\/stemcells.2006-0466"},{"key":"BFsrep45641_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.109.871905","volume":"121","author":"XL Tang","year":"2010","unstructured":"Tang, X. L. et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation 121, 293\u2013305 (2010).","journal-title":"Circulation"},{"key":"BFsrep45641_CR31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/dvdy.1200","volume":"222","author":"U Ozerdem","year":"2001","unstructured":"Ozerdem, U., Grako, K. A., Dahlin-Huppe, K., Monosov, E. & Stallcup, W. B. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn. 222, 218\u2013227 (2001).","journal-title":"Dev. Dyn."},{"key":"BFsrep45641_CR32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/stem.1868","volume":"33","author":"WCW Chen","year":"2015","unstructured":"Chen, W. C. W. et al. Human myocardial pericytes: Multipotent mesodermal precursors exhibiting cardiac specificity. Stem Cells 33, 557\u2013573 (2015).","journal-title":"Stem Cells"},{"key":"BFsrep45641_CR33","doi-asserted-by":"crossref","unstructured":"Eder, A. et al. Effects of proarrhythmic drugs on relaxation time and beating pattern in rat engineered heart tissue. Basic Res. Cardiol. 109 (2014).","DOI":"10.1007\/s00395-014-0436-7"},{"key":"BFsrep45641_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejphar.2004.07.013","volume":"500","author":"M Endoh","year":"2004","unstructured":"Endoh, M. Force-frequency relationship in intact mammalian ventricular myocardium: Physiological and pathophysiological relevance. Eur. J. Pharmacol. 500, 73\u201386 (2004).","journal-title":"Eur. J. Pharmacol."},{"key":"BFsrep45641_CR35","doi-asserted-by":"publisher","first-page":"e23657","DOI":"10.1371\/journal.pone.0023657","volume":"6","author":"H Uosaki","year":"2011","unstructured":"Uosaki, H. et al. Efficient and Scalable Purification of Cardiomyocytes from Human Embryonic and Induced Pluripotent Stem Cells by VCAM1 Surface Expression. PLoS One 6, e23657 (2011).","journal-title":"PLoS One"},{"key":"BFsrep45641_CR36","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1161\/CIRCRESAHA.110.239574","volume":"108","author":"M Bauer","year":"2011","unstructured":"Bauer, M. et al. Echocardiographic speckle-tracking based strain imaging for rapid cardiovascular phenotyping in mice. Circ. Res. 108, 908\u2013916 (2011).","journal-title":"Circ. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep45641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep45641","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/srep45641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/srep45641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:07:03Z","timestamp":1671840423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep45641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,3]]}},"alternative-id":["BFsrep45641"],"URL":"https:\/\/doi.org\/10.1038\/srep45641","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,3]]},"assertion":[{"value":"30 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.K.Y. is a founder, equity holder, and scientific adviser of iHeart Japan Corporation. J.K.Y. and H.M. are co-inventors on multiple pluripotent stem cell-related patents.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45641"}}